BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 26, 2026
Home » Authors » Alex Ho

Articles by Alex Ho

Chinese drugmakers ride wave of VAT cuts on rare diseases

Feb. 27, 2019
By Alex Ho
HONG KONG – Chinese drugmakers have gotten a boost in the wake of the Chinese government's announcement to cut the value-added tax (VAT) on treatments for a range of rare diseases, in the country's latest move to overhaul its health care system and expand access to better-quality and cheaper drugs.
Read More

Chinese drugmakers ride wave of VAT cuts on rare diseases

Feb. 25, 2019
By Alex Ho
HONG KONG – Chinese drugmakers have gotten a boost in the wake of the Chinese government's announcement to cut the value-added tax (VAT) on treatments for a range of rare diseases, in the country's latest move to overhaul its health care system and expand access to better-quality and cheaper drugs.
Read More

Shares of Chinese drugmakers plunge amid moves to cut prices of generics

Dec. 19, 2018
By Alex Ho
HONG KONG – Chinese drugmakers' stocks hit their worst slump since 2008 last week on reports of a government pilot program aimed at lowering generic drug prices.
Read More

Shares of Chinese drugmakers plunge amid moves to cut prices of generics

Dec. 13, 2018
By Alex Ho
HONG KONG – Chinese drugmakers' stocks hit their worst slump since 2008 last week on reports of a government pilot program aimed at lowering generic drug prices.
Read More

Indian pharmas alert to yuan convertibility proposal

Nov. 21, 2018
By Alex Ho
HONG KONG – The Indian government reportedly made moves in late October to prevent the rupee from falling further against the U.S. dollar. While the Indian currency is expected to benefit from the proposed plan, local pharmaceutical firms are likely to suffer from a stronger rupee.
Read More

Indian life science firms alert to yuan convertibility proposal

Nov. 20, 2018
By Alex Ho

Indian pharmas alert to yuan convertibility proposal

Nov. 20, 2018
By Alex Ho
HONG KONG – The Indian government reportedly made moves in late October to prevent the rupee from falling further against the U.S. dollar. While the Indian currency is expected to benefit from the proposed plan, local pharmaceutical firms are likely to suffer from a stronger rupee.
Read More

Innovent bucks trend with solid debut, but HKEX shaky for biotech so far this year

Nov. 7, 2018
By Alex Ho

HONG KONG – A wave of bad news, not least of which is a faulty vaccines scandal in China, has hit Hong Kong-listed biotechnology stocks hard in 2018. However, on Oct. 31, Innovent Biologics Inc. debuted on the Hong Kong Stock Exchange with a surprising 19 percent price jump, breaking the curse of sharp price drops when the previous three biotech flotations first began trading.


Read More

Innovent bucks trend with solid debut, but HKEX shaky for biotech so far this year

Nov. 1, 2018
By Alex Ho
HONG KONG – A wave of bad news, not least of which is a faulty vaccines scandal in China, has hit Hong Kong-listed biotechnology stocks hard in 2018. However, on Oct. 31, Innovent Biologics Inc. debuted on the Hong Kong Stock Exchange with a surprising 19 percent price jump, breaking the curse of sharp price drops when the previous three biotech flotations first began trading.
Read More

Hansoh joins growing HKEX IPO queue, undeterred by volatility; China to follow?

Sep. 12, 2018
By Elise Mak and Alex Ho
HONG KONG – China-based Hansoh Pharmaceutical Group Co. Ltd. has filed for an IPO in Hong Kong, making it the 11th biopharma company to seek a listing on the Hong Kong Stock Exchange (HKEX) since May and following Ascentage Pharma Group International's IPO a week earlier.
Read More
Previous 1 2 3 4 5 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

    BioWorld Science
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
  • Illustration of head with maze that is missing parts

    Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

    BioWorld Science
    Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
  • Pill in immersive interface

    New mechanism of action identified for QC-6352

    BioWorld Science
    QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
  • Illustration of brain and antibodies

    VST Bio’s VB-001 is neuroprotector after stroke

    BioWorld Science
    At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing